Dr. Flajolet’s research led to the discovery that a protein called CK1 regulates the production of beta-amyloid in the brain, suggesting that inhibitors of this protein might be useful in treating Alzheimer’s disease. He is involved in the development and optimization of novel imaging techniques, such as iDISCO, to detect Alzheimer’s disease hallmarks. Dr. Flajolet also collaborates with other Fisher scientists to identify novel therapeutic targets by focusing on a class of receptors called GPCRs. He is also currently developing a novel type of molecular tool that could considerably speed-up drug-discovery for the treatment of AD.